Evoke Pharma (NASDAQ:EVOK) Stock Scheduled to Reverse Split on Thursday, August 1st

Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) are set to reverse split on the morning of Thursday, August 1st. The 1-12 reverse split was announced on Thursday, August 1st. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, August 1st.

Evoke Pharma Stock Down 16.4 %

Evoke Pharma stock traded down $0.08 during trading hours on Tuesday, hitting $0.42. The stock had a trading volume of 112,058 shares, compared to its average volume of 42,557. The business’s 50 day simple moving average is $0.52 and its 200-day simple moving average is $0.57. Evoke Pharma has a one year low of $0.36 and a one year high of $1.67. The stock has a market cap of $3.59 million, a price-to-earnings ratio of -0.23 and a beta of 0.38.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The firm had revenue of $1.74 million during the quarter.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Evoke Pharma in a research note on Tuesday, July 23rd. They issued a “sell” rating on the stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.